IMV News and Press, IMV Inc. From 03/08/21

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Wednesday, March 17, 2021 at 8:00 a.m. Ea...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team ...

Point Roberts, WA and Delta, BC - February 12, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Green Energy and Gaming. Today�s stocks have been...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team ...

IMV (IMV) rises 16% premarket after providing an update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection. The Company has successfully completed preclinical safety, GLP toxicology as well as immunogenicity and challenge studies conf...

Preclinical safety, long duration of antibody titers and potential for protection demonstrated in preclinical immunogenicity and challenge studies Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months and ongoing Preclinical stu...

Company’s next milestone is to meet with FDA in Q1 2021 to design next clinical trial in collaboration with Merck PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits IMV Inc. (Nasdaq:IMV...

Phoenix New Media (FENG) +115%.Lizhi (LIZI) +97% on collaboration with Xpeng MotorsEver-Glory International Group (EVK) +85%.Nesco Holdings (NSCO) +51% after announcing acquisition of Custom Truck One Source for $1.475B.Cyanotech Corporation (CYAN) +42%.Waddell & Reed Financial ...

IMV (IMV) announces updated data from a Phase 2 clinical trial, DeCidE1, evaluating DPX-Survivac, combined with intermittent low-dose cyclophosphamide (chemo agent), in patients with recurrent advanced platinum-sensitive and platinum-resistant ovarian cancer.78.9% (n=15/19) of evaluable patie...

37% (7/19) patients experienced clinical benefits lasting over 6 months 12-month overall survival rate of 66.1% Translational data confirms survivin-specific CD8+ T cell immune response in 87% of subjects which supports a direct link with DPX-Survivac’...